Alnylam Pharmaceuticals, Inc. (ALNY) Investor Relations Documents

Alnylam Pharmaceuticals, Inc. (ALNY) investor relations documents from the company's IR site: 12 presentations, 17 press releases; latest deck 2026-07-30. Read in-app with summaries. First-party data.

Earnings deck: Alnylam Pharmaceuticals reported Q2 2026 total net product revenues of $1.172 billion, a 74% year-over-year increase, driven by strong TTR franchise performance.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-30Press releasePress release
2026-07-30Earnings deckEarnings deck
2026-07-30Press releaseAlnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
2026-07-16Press releasePress release
2026-07-16Press releaseAlnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
2026-07-15Press releaseAlnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Diseas
2026-06-24PresentationRNAi Roundtable: ALN-6400, Targeting Plasminogen to Address Rare Bleeding Disorders View the Presentation ›
2026-06-12Press releaseAlnylam to Host Tenth “RNAi Roundtable” Webcast Series
2026-06-03Press releaseAlnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
2026-05-15ESG reportDownload
2026-05-12Press releaseNew Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a
2026-05-12Press releaseNew Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a
2026-05-07Press releaseAlnylam to Webcast Presentations at Upcoming Investor Conferences
2026-05-04Press releaseAlnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
2026-05-04Press releaseAlnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Press releaseAlnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
2026-04-30Press releaseAlnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
2026-04-30Earnings deckVIEW PDF ›
2026-04-06Proxy statementProxy statement
2026-03-31Annual reportDownload
2026-03-24Investor meetingInvestor meeting
2026-02-12Press releasePress release
2026-02-12Earnings deckEarnings deck
Press releasePress release
2025-10-30Earnings deckPresentation ›
2025-10-29Earnings deckGAAP/Non-GAAP Reconciliation ›
Press releasePress release
2025-07-31Earnings deckPresentation ›
2025-07-30Earnings deckGAAP/Non-GAAP Reconciliation ›
2025-05-01Earnings deckPresentation ›
2025-05-01Earnings deckGAAP/Non-GAAP Reconciliation ›
2025-04-01ESG reportDownload PDF
2022-09-13PresentationDownload ›
DocumentPage 168

ALNY overview · ALNY earnings · ALNY financials · ALNY KPIs · ALNY documents · ALNY ownership · ALNY peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.